Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AIC100||AIC-100|AIC 100||AIC100 is a cell therapy consisting of T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the intercellular adhesion molecule-1 (ICAM-1), and CD28, potentially leading to activation of inhibitory T cells, inhibition of cell proliferation and inhibition of tumor growth (PMID: 31337787, NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04420754||Phase I||AIC100||Study of AIC100 in Relapsed/Refractory Thyroid Cancer||Recruiting||USA||0|